Company Overview of Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals Corporation develops drug candidates to address significant diseases of the eye. The company specializes in developing molecules with novel mechanisms of action to fulfill unmet medical needs in significant diseases of the eye. Its product INO-8875 is an Adenosine-1 receptor agonist and potential eye-drop product for the treatment of elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension. The company’s products also include polymerase inhibitors and superoxide dismutase mimetics that alleviate oxidative injury and inflammation for medical needs in retinal diseases. Inotek Pharmaceuticals Corporation was formerly known as Inotek Corpor...
33 Hayden Avenue
Lexington, MA 02421
Founded in 1996
Key Executives for Inotek Pharmaceuticals Corporation
Chief Medical Officer and Executive Vice President
Compensation as of Fiscal Year 2014.
Inotek Pharmaceuticals Corporation Key Developments
Inotek Pharmaceuticals Announces Study Results Demonstrating Neuroprotective Properties of Trabodenoson
May 30 14
Inotek Pharmaceuticals Corporation announced the results from a preclinical study demonstrating the ability of trabodenoson, an adenosine A1 mimetic in development for glaucoma, to protect against the loss of retinal ganglion cells in an acute high-ocular-pressure animal model of glaucoma. Retinal ganglion cells are the part of the nervous system responsible for relaying the visual image from the eye to the brain, and their death is what causes the irreversible vision loss associated with glaucoma. The results of this study were presented this month at the 2014 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). This preclinical neuroprotection study was designed to compare the protective effects of trabodenoson and brimonidine in a rat model of ischemia-induced retinal ganglion cell (RGC) death. Trabodenoson was delivered as an eye drop at a clinically relevant dose. Results of the study showed that trabodenoson provided 100% protection against the thinning of the ganglion cell layer (p<=0.001 compared to vehicle-treated eyes).
Inotek Pharmaceuticals Initiates Phase 2 Study with Trabodenoson in Combination with Latanoprost for Patients with Glaucoma or Ocular Hypertension
Mar 10 14
Inotek Pharmaceuticals Inc. announced the initiation of a Phase 2 clinical study of its lead product, trabodenoson, in combination with the most widely-prescribed glaucoma drug, the prostaglandin analog latanoprost (LAT), in patients with elevated intraocular pressure (IOP) that remains uncontrolled despite ongoing treatment with latanoprost. The Phase 2 study is a randomized, double-masked, active-controlled, multicenter trial comparing trabodenoson plus LAT, to timolol (the active comparator) plus LAT, in 120 patients with ocular hypertension (OHT) or primary open-angle glaucoma (POAG). The study will measure the additive or synergistic IOP lowering effect of trabodenoson when combined with LAT, and will also evaluate the safety and tolerability of the combined treatment regimen. The total treatment time will be 3 months, during which the effect of trabodenoson will be evaluated following twice-a-day dosing (BID) and once-daily dosing (QD). Top line data is expected in the fourth quarter of 2014.
Inotek Pharmaceuticals Corp. Closes $21 Million Financing
Oct 3 13
Inotek Pharmaceuticals Corp. announced that it has closed on a $21 million financing. According to a release, proceeds from this financing will be used to advance Inotek's lead product, trabodenoson, a novel eye drop that increases aqueous fluid outflow via the eye's trabecular meshwork, through phase 2 studies in glaucoma.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries